Key Developments for Pacira BioSciences, Inc. Shareholders
Attention shareholders! Recent events have significantly affected shares of Pacira BioSciences, Inc. (NASDAQ: PCRX). If you were an investor during the recent class period, it is crucial to stay informed about your options concerning potential recourse. You may have noticed a steep decline in the stock price following pivotal news announcements that have raised concerns among shareholders.
Understanding the Recent Stock Price Decline
On August 9, 2024, Pacira revealed alarming information regarding a lawsuit against a competitor, eVenus, over patent infringement. The court ruled that Pacira's U.S. Patent No. 11,033,495, which covers Exparel—a product contributing to roughly 80% of the company's revenue—was not valid. This invalidation raised several significant red flags about the viability of Pacira's other patents, thereby posing a risk of increased market competition due to generic entries.
As a consequence of this news, Pacira's stock saw a harsh downturn. It plummeted from a closing price of $22.36 on August 8, 2024, to a low of $11.70 on August 9, 2024. This dramatic decrease of over 47% took many shareholders by surprise and led to concerns about the long-term effects on the company's market position.
What This Means for Shareholders
Given the situation, shareholders who purchased shares of PCRX during the specified class period are strongly encouraged to get in touch with legal professionals who can assist with any necessary actions. Particular attention should be paid to the stated deadline of March 14, 2025, for those wishing to be named lead plaintiffs in potential class actions.
Engaging in this process does not require shareholders to take on any financial burdens; there is no fee associated with registering for participation. By registering, you will benefit from robust monitoring of the case status as it unfolds.
Next Steps and Important Deadlines
It is vital to act promptly. Registering as a shareholder allows you to receive updates on developments in this case. You will automatically be enrolled in portfolio monitoring services, which can help keep you informed about any potential recoveries from losses you may have incurred. Remember, the lead plaintiff appointment deadline is set for March 14, 2025, a date that every concerned shareholder should note.
Understanding the Role of Legal Assistance
The Gross Law Firm is a recognized entity within the world of class action lawsuits and represents shareholders who have lost money due to misleading business practices. Their commitment lies in safeguarding the rights of investors, ensuring transparency, and striving for accountability among corporations. By advocating for investors, the firm aims for recoveries when false or misleading claims inflate stock values artificially, leading to losses when the truth is uncovered.
For any shareholders seeking to understand their rights and options in the wake of recent developments, contacting The Gross Law Firm can be an effective first step towards safeguarding one's investments.
Contact Information
In case of any inquiries or to initiate the process, shareholders can reach out to The Gross Law Firm directly at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the recent news regarding Pacira BioSciences?
Pacira BioSciences faced a significant patent ruling that affected the validity of their key patents, resulting in a dramatic drop in stock price.
What should shareholders of PCRX do now?
Shareholders should consider contacting legal professionals to discuss their options for potential participation in a class action lawsuit.
What is the deadline for registering to be a lead plaintiff?
The deadline to register for consideration as a lead plaintiff is March 14, 2025.
Is there a cost to participate in the class action?
No, there are no costs involved in registering or participating in the class action case.
What is the role of The Gross Law Firm?
The Gross Law Firm specializes in class actions and aims to protect the rights of shareholders who may have suffered losses from corporate misconduct.
